DRUG-ELUTING MEDICAL DEVICES

• US 20150209299A1
• Filed: 01/28/2015
• Published: 07/30/2015
• Est. Priority Date: 01/29/2014
• Status: Abandoned Application

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Xia, Zhiyong, Hwang, Chao-Wei
• Application Number:
  US14/607,106
• Publication Number:
  US 20150209299A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/616 by carboxylic acids, e.g. acetylsalicylic acid
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61L 2300/624 Nanocapsules
• CPC Class Codes: A61L 2400/12 Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

A medical device includes a plurality of drug-eluting nanofibers directly or indirectly located over an outer surface of the medical device, or utilized independently as a tissue engineering scaffold. The plurality of drug-eluting nanofibers include one or more therapeutic agents. Additional embodiments include a fabric having a plurality of drug-eluting nanofibers, in which the plurality of drug-eluting nanofibers include one or more therapeutic agents

Claims

1. A device, comprising:

(a) a medical device; and

(b) a plurality of drug-eluting nanofibers directly or indirectly located over an outer surface of the medical device;

wherein the plurality of drug-eluting nanofibers comprise one or more therapeutic agents.

2. The device according to claim 1, wherein the plurality of drug-eluting nanofibers comprise a sheath-and-core configuration comprising a core and a sheath surrounding the core;

wherein the core comprises the one or more therapeutic agents.

3. The device of claim 2, wherein the core and the sheath each comprise a biodegradable polymer;

said core may comprise the same or different biodegradable polymer of the sheath.

4. The device of claim 1, wherein the plurality of drug-eluting nanofibers comprise a hollow-fiber configuration comprising an outer wall defining an interior cavity.

5. The device of claim 4, wherein the one or more therapeutic agents is located at least in the interior cavity.

6. The device of claim 4, wherein the interior cavity comprises a therapeutic composition comprising the one or more therapeutic agents.

7. The device of claim 6, wherein the therapeutic composition comprises a solution, suspension, gel, solid-preparation or any combinations thereof.

8. The device of claim 7, wherein the plurality of drug-eluting nanofibers comprise one or more seals configured to temporarily contain the therapeutic composition within the interior cavity.

9. The device of claim 8, wherein the one or more seals comprise a mechanical crimp, thermally formed seal, or combination thereof.

10. The device of claim 1, wherein the plurality of drug-eluting nanofibers comprise a porous-outer surface comprising a plurality of pores.

11. The device of claim 10, wherein the plurality of pores comprise the one or more therapeutic agents disposed therein.

12. The device of claim 11, wherein the plurality of pores comprise an average diameter, an average depth, or both from about 5 nm to about 1000 nm.

13. The device of claim 11, wherein the plurality of pores comprise pit-like structure.

14. The device of claim 1, wherein the plurality of drug-eluting nanofibers comprise a nonwoven fabric positioned directly or indirectly over the outer surface of the medical device.

15. The device of claim 1, wherein the nonwoven fabric comprises a sleeve.

16. A fabric, comprising a plurality of drug-eluting nanofibers, wherein the plurality of drug-eluting nanofibers comprise one or more therapeutic agents.

17. The fabric of claim 16, wherein the plurality of drug-eluting nanofibers comprise a sheath-and-core configuration, a hollow-fiber configuration, a porous-outer surface comprising a plurality of pores, or any combination thereof.

18. A tissue engineering scaffold, comprising a fabric, wherein the fabric comprises a plurality of drug-eluting nanofibers, and wherein the plurality of drug-eluting nanofibers comprise one or more therapeutic agents.

19. The tissue engineering scaffold of claim 18, wherein the tissue engineering scaffold comprises at least a first drug-eluting fiber configured for releasing a first therapeutic agent and a second drug-eluting fiber configured for releasing a second therapeutic agent.

20. The tissue engineering scaffold of claim 19, wherein the first drug-eluting fiber is located within a first layer of the tissue engineering scaffold and the second drug-eluting fiber is located within a second layer of the tissue engineering scaffold.